menu
    • menu
    [{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Molecular glue","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ GSK"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein degradation","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Evotec","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"EVT801","moa":"VEGF3 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evotec \/ Kazia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Evotec","sponsor":"OncoResponse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"OR2805","moa":"CD163","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ OncoResponse","highestDevelopmentStatusID":"7","companyTruncated":"Evotec \/ OncoResponse"},{"orgOrder":0,"company":"Rigenerand","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RR001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Rigenerand","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigenerand \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rigenerand \/ Inapplicable"},{"orgOrder":0,"company":"Evotec","sponsor":"Peptone","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Evotec"}]

    Find Oncology Clinical Drug Pipeline Developments & Deals by Evotec

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Peptone

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Peptone Partners with Evotec to Target IDPs and Scale Small-Molecule Therapies

                            Details : Through the partnership, Peptone will harness Evotec's drug discovery toolbox, encompassing deep domain expertise in oncology and immunology.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 08, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Peptone

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $5,200.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Evotec And Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership

                            Details : Under the expanded collaboration, the companies will develop the pipeline of molecular glue degraders. The companies will leverage all of Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms as well as AI/ML-based drug discovery and development ...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $200.0 million

                            March 28, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $5,200.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $5,200.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

                            Details : Evotec has significantly scaled up its activities to develop compounds from BMS’s industry-leading library of cereblon E3 ligase modulators and continues to build a leading pipeline of novel molecular glue degraders, targeting high-value targets in the...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $200.0 million

                            March 16, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $5,200.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : GSK

                            Deal Size : $350.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies

                            Details : The collaboration focuses on the development of first-in-class targeted immune-based therapies for oncology. The collaboration leverages Evotec’s integrated discovery and development capabilities and manufacturing optimisation processes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 26, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : GSK

                            Deal Size : $350.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evotec and Bristol Myers Squibb to Extend Their Targeted Protein Degradation Partnership

                            Details : The partnership leverages Evotec’s proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with the integrated data analysis platform PanHunter.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 26, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVT801

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Kazia Therapeutics

                            Deal Size : $366.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Evotec Enters Partnership with Kazia Therapeutics for Clinical Development of EVT801

                            Details : Evotec will grant Kazia an exclusive worldwide license for research, development and commercialization of Evotec's oncology project EVT801. EVT801 is a pre-clinical-stage, orally available, small molecule inhibitor of the lymphatic growth factor receptor...

                            Product Name : EVT801

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 19, 2021

                            Lead Product(s) : EVT801

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Kazia Therapeutics

                            Deal Size : $366.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $160.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evotec Enters Agreement with Takeda Pharma to Discover & Develop RNA Targeting Small Molecule Therapeutics

                            Details : The collaboration will leverage Evotec’s extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 22, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $160.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Rigenerand

                            Italy arrow
                            APGA Annual Conference
                            Not Confirmed

                            Rigenerand

                            Italy arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RR001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rigenerand Receives Regulatory Approval for Gene Therapy Production

                            Details : This authorization enables Rigenerand to manufacturer its own autologous gene therapy medicinal product (RR001) for the treatment of pancreatic cancer. It also authorizes the company to start its phase I first-in-man clinical trial of RR001.

                            Product Name : RR001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 06, 2020

                            Lead Product(s) : RR001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed

                            Evotec

                            Germany arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OR2805

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : OncoResponse

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Just – Evotec Biologics announces product development and manufacturing agreement with OncoResponse

                            Details : Under the agreement, Just – Evotec Biologics will leverage its integrated technology platform, J.DESIGN, to provide OncoResponse with services to accelerate OR2805 into the clinic.

                            Product Name : OR2805

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 16, 2020

                            Lead Product(s) : OR2805

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : OncoResponse

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth